MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia’s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis. The transaction is valued at up to US$1.5 billion (~A$2.16bn) including an upfront cash payment of US$1.1 billion (~A$1.58bn) plus potential mile
Finance GlobalNewswire Jul 6, 2026